Ibsrela vs Motegrity
A side-by-side look at two gastrointestinal medications advertised on TV. Informational only — not medical advice.
| US Ibsrela | US Motegrity | |
|---|---|---|
| Generic name | tenapanor | prucalopride |
| Drug class | Sodium/Hydrogen Exchanger 3 (NHE3) Inhibitor | Serotonin-4 Receptor Agonist |
| Treats | Irritable bowel syndrome with constipation (IBS-C) | Chronic idiopathic constipation |
| Category | Gastrointestinal | Gastrointestinal |
| Manufacturer | Ardelyx | Takeda |
| Year approved | 2019 | 2018 |
| FDA warning | Black box warning | Moderate warnings |
| Est. TV ad spend | — | — |
| Common side effects | Diarrhea, Should not be used in young children (boxed warning), Gas, Abdominal pain | Headache, Abdominal pain, Nausea, Diarrhea |
Motegrity
Frequently asked questions
Is Ibsrela or Motegrity better?
Neither is universally "better." Ibsrela (tenapanor) and Motegrity (prucalopride) are both used for gastrointestinal, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Ibsrela and Motegrity?
Ibsrela is a Sodium/Hydrogen Exchanger 3 (NHE3) Inhibitor made by Ardelyx, while Motegrity is a Serotonin-4 Receptor Agonist made by Takeda. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Ibsrela has the larger estimated TV advertising budget of the two.